Gilead Sciences, Inc. (GILD)

Gilead Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4,718	6,085	5,412	5,338	5,997	11,631
Short-Term Investments	0	1,179	973	1,182	1,411	12,721
Cash & Cash Equivalents	4,718	7,264	6,385	6,520	7,408	24,352
Cash Growth	-19.65%	13.77%	-2.07%	-11.99%	-69.58%	-19.07%
Receivables	4,669	4,660	4,777	4,493	4,892	3,582
Inventory	1,853	1,787	1,507	1,618	1,683	922
Other Current Assets	2,801	2,374	1,774	2,141	2,013	1,440
Total Current Assets	14,041	16,085	14,443	14,772	15,996	30,296
Property, Plant & Equipment	5,321	5,317	5,475	5,121	4,967	4,502
Long-Term Investments	0	1,163	1,245	1,309	502	1,488
Goodwill and Intangibles	31,742	34,768	37,208	41,787	41,234	17,903
Other Long-Term Assets	5,188	4,792	4,800	4,963	5,708	7,438
Total Long-Term Assets	42,251	46,040	48,728	53,180	52,411	31,331
Total Assets	56,292	62,125	63,171	67,952	68,407	61,627
Accounts Payable	622	550	905	705	844	713
Current Debt	3,667	1,798	2,273	1,516	2,757	2,499
Other Current Liabilities	8,726	8,932	8,059	9,389	7,796	6,547
Total Current Liabilities	13,015	11,280	11,237	11,610	11,397	9,759
Long-Term Debt	21,527	23,189	22,957	25,179	28,645	22,094
Other Long-Term Liabilities	4,295	4,907	7,768	10,099	10,144	7,124
Total Long-Term Liabilities	25,822	28,096	30,725	35,278	38,789	29,218
Total Liabilities	38,837	39,376	41,962	46,888	50,186	38,977
Total Debt	25,194	24,987	25,230	26,695	31,402	24,593
Debt Growth	-0.18%	-0.96%	-5.49%	-14.99%	27.69%	-9.99%
Retained Earnings	10,656	16,304	15,687	16,324	14,381	19,388
Comprehensive Income	69	28	2	83	-60	85
Shareholders' Equity	17,539	22,833	21,240	21,069	18,202	22,525
Net Cash / Debt	-20,476	-17,723	-18,845	-20,175	-23,994	-241
Net Cash Per Share	-16.42	-14.09	-14.93	-15.99	-19.00	-0.19
Working Capital	1,026	4,805	3,206	3,162	4,599	20,537
Book Value Per Share	14.06	18.30	16.92	16.77	14.48	17.74

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).